Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
15 participants
OBSERVATIONAL
2023-12-08
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question\[s\] it aims to answer are:
* will the cardiac arrythmia be removed and remain absent oc recurrent also 3 months after procedure
* what are the adverse events at procedure, after 3 and 6 months
All participants will receive cardiac ablation with EasyCool catheter.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Endocavitary Electrical Signal and Surface Electrocardiogram to Predict Ablation Outcome in Persistent Atrial Fibrillation
NCT03937089
The Use of Remote Magnetic Navigation in Catheter Ablation of Heart Arrythmia
NCT00524602
Cavo-Tricuspid Isthmus Block Durability After Pulsed Electric Field Ablation
NCT06691074
Remote MAGNetic Catheter Ablation for Atrial Fibrillation
NCT02587624
Real Zero Fluoroscopy Catheter Ablation.
NCT03458273
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Age \<12 years;
* Pregnancy or breast-feeding women;
* Acute local infection;
* Acute systemic infection;
* Atrial thrombosis or myxoma - the transseptal approach is contraindicated in patients with left atrial thrombus;
* Existence of active Implants (Pacemaker, Defibrillator etc.);
* Hemodynamic instability;
* Hypercoagulability;
* Inadequate tissue damaged e.g. by radiation or suppuration;
* Obstruction of the artery or vein selected for insertion;
* Patients with artificial heart valve: the use of intracardial catheters is not advised;
* Physiologic or anatomic abnormalities that could cause postoperative complications e.g. aneurysms in the application area, bleeding diathesis, decreased resistance to infections;
* Previously diagnosed spasms of the coronary arteries;
* Recurrent metastasizing cancer;
* Sepsis;
* Severe concomitant illness for which an increase or surgery time is associated with a significant increased risk;
* Thrombosis of the leg veins and the deep pelvic vein.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedFact Engineering GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abdeddayem Haggui, Prof
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier International de Carthagène, Tunisia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier International de Carthagène
Tunis, Centre Urbain Nord, Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT04-01_EasyCool
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.